T-Knife Therapeutics
Edit info- Founded: 2018
- Location: Berlin, Germany
- Employee range: 50 - 200
- Clinical stage: Clin1/Clin2
- Therapy area: Solid tumors
- Drug types: ONC
- Lead product: TK-8001
- Funding: $110M B Jul 2021; $78M A Aug 2020
- Investors: Versant Ventures
t-knife.com linkedin.com job board
Drug notes:
TK-2504 Clin0 solid tumors; TK-1412 RD oncology; TK-1112 RD oncology; TK-0118 RD oncology
About:
T-Knife Therapeutics is developing novel T cell engineered therapeutics to fight cancer. T cell receptor (TCR) engineered T cells are a promising new therapeutic modality. T-Knife is discovering high affinity and high specificity human TCRs that can be used to supercharge T cells. Through the use of natural, fully human TCRs and tailored armoring, T-Knife’s product candidates are designed to optimize the immune signaling cascade to drive potent T cell responses against tumors. T-Knife’s pipeline includes TCR therapies that target tumor antigens in multiple, difficult to treat solid tumor indications.
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com